Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy ; volume:30 ; number:1 ; day:20 ; month:1 ; year:2024 ; pages:1-16 ; date:12.2024
Molecular medicine ; 30, Heft 1 (20.1.2024), 1-16, 12.2024

Creator: Qin, Ge
Bai, Fan
Hu, Huabin
Zhang, Jianwei
Zhan, Weixiang
Wu, Zehua
Li, Jianxia
Fu, Yang
Deng, Yanhong

Contributor: SpringerLink (Online service)

DOI: 10.1186/s10020-024-00780-4

URN: urn:nbn:de:101:1-2024033121252589832576

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 2:30 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Qin, Ge
Bai, Fan
Hu, Huabin
Zhang, Jianwei
Zhan, Weixiang
Wu, Zehua
Li, Jianxia
Fu, Yang
Deng, Yanhong
SpringerLink (Online service)

Other Objects (12)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Related objects

Reset password